title: Azacitidine-eligibility in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukaemia: a registry-based study.
authors.affiliation: Dundee Cancer Centre, Ninewells Hospital, Dundee, UK.
authors.forename: Senthilkumar
authors.initials: S
authors.lastname: Durairaj
authors.forename: Norene
authors.initials: N
authors.lastname: Keenan
authors.forename: Ann
authors.initials: A
authors.lastname: Hyslop
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Groves
authors.forename: David T
authors.initials: DT
authors.lastname: Bowen
authors.forename: Sudhir
authors.initials: S
authors.lastname: Tauro
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D001374:Azacitidine / Q000008:administration & dosage*; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality*; D012042:Registries; D012189:Retrospective Studies
chemical_list: D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine; D001374:Azacitidine